The multi cancer early detection market size is estimated to be USD 798.92 million in 2022 and is expected to witness a CAGR of 15.95% during the forecast period 2023-2033. Increasing prevalence of cancer and its various forms and the requirement to provide efficient methods for early cancer detection. are projected to drive the market growth in near future. Furthermore, improving diagnostic performance, MCED is currently undergoing extensive research and development is projected to support the market growth. However, negative health effects and increasing production cost are predicted to limit market growth are expected to restrain the market growth.

Increasing prevalence of cancer and its various forms is expected to propel the market. According to the WHO, cancer account for about 10 million deaths in 2020, or nearly one in every six, putting it as the leading cause of death worldwide. One-third of cancer-related deaths are driven by variables like smoking, having a high body mass index, drinking, obesity, and raised cholesterol.

Improving diagnostic performance, MCED is currently undergoing extensive research and development is predicted to fuel the market growth. For instance, Elypta initiated the Multi-Cancer Early Detection research in July 2022 in collaboration with Yorkshire Cancer Research and the University of Leeds to measure the levels of the metabolic GAGOme in persons at high risk for getting cancer. The research was based on proof-of-concept findings that were displayed at the American Society of Clinical Oncology meeting in June 2021, which demonstrated that GAGOmes could identify one-third of all stage I tumors in 14 different cancer types, including lung and kidney cancer.

Segmentation

 By Type

The market is categorized into liquid biopsy, gene panel, LDT, and others. In 2022, the gene panel, LDT, and others segment accounted for the highest revenue share due to the fact that gene panels aims the identification of hereditary cancers and growing public awareness of hereditary diseases. The liquid biopsy segment is anticipated to develop at the fastest rate over the projection period due to increasing acceptance of cancer detection. Although scientists have long speculated about the prospect of identifying cancer through blood analysis and have known since the 1960s that free-floating DNA exists in blood, the World Economic Forum has designated liquid biopsy as one of the top 10 emerging technologies in the world.

 By End User

The market is categorized into diagnostic laboratories, hospitals, and others. In the global market, the hospitals segment accounted for the largest revenue share in 2022 owing to prevalence of specialised doctors and other medical professionals. Hospitals are used as a platform to inform and raise public knowledge of various diseases and ailments. The target audience knows very less about MCED, which is a new technology. As a result, asymptomatic people are examined in hospitals for many types, which facilitates treatment. Diagnostic laboratories are anticipated to have significant expansion over the projection period due to surge in testing and the availability of resources for conducting tests. The segment is expanding at an accelerated rate due to hospitals’ greater dependency on diagnostic laboratories for testing and evaluation.

Regional Markets

In 2022, Europe region accounted for the highest revenue in the multi cancer early detection market and is expected to maintain its dominance during the forecast period. This is attributed to expanding investment in R&D and rise in cancer incidence. For instance, the EU-funded DeteCTCs project aims to fasten the commercialization of the CellMate innovation to improve cancer patients’ ability to be diagnosed and treated. CellMate uses AI-powered bioinformatics, DNA sequencing, and cutting-edge universal circulating cancer cell capture and recognition technology to simultaneously identify multiple cancer types at an early stage with just one blood draw. North America is anticipated to exhibit the fastest growth over the forecast period. A substantial study of a single MCED test has started in the US. Within the next 18 to 24 months, a significant NCI-funded trial with an unknown start date will probably get launched in the United States and will involve many MCED tests. Additionally, it’s projected that the region’s expanding cancer incidence will support market growth. For instance, the American Cancer Society predicts that 1.9 million new cases of cancer will be diagnosed worldwide in 2021, and that over 600,000 individuals will die of old age from the disease. This amounts to almost 1,650 deaths every day.

Competitor Insights

Some of the key players operating in the multi cancer early detection market are Grail, LLC, GENECAST, Laboratory for Advanced Medicine, Inc., AnchorDx, Guardant Health, Inc., Burning Rock Biotech Limited, Foundation Medicine, Inc., Exact Sciences Corporation., Illumina, Inc., and Singlera Genomics Inc.

The key market competitors are emphasizing on research and development and screening the created detection test on a huge population pool to comprehend and test the test’s usefulness.

• For instance, Grail, LLC announced in July 2022 that enrollment for the NHS-Galleri study was finished in less than 10 months. The research, which is the largest-ever study of a multi-cancer early detection test, has included 140,000 healthy participants.
• Grail, a major participant in the market, employs a number of strategies to boost product adoption and reach through strategic initiatives. For instance, the U.S. Department of Veterans Affairs announced in May 2022 a partnership with Grail for the screening of 10,000 veterans at 10 locations using the Galleri Test.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including type and end user from 2022 to 2033

Report Scope:

Segmentation: Multi Cancer Early Detection Market Report 2022 – 2033

Type (Revenue, USD Million), 2022 – 2033

• Liquid Biopsy
• Gene Panel, LDT & Others

End user (Revenue, USD Million), 2022 – 2033

• Diagnostic Laboratories
• Hospitals
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA